Levetiracetam Increases Hippocampal Blood Flow in Alzheimer’s Disease as Measured by Arterial Spin Labelling MRI

Abstract

Administration of 2.5 mg/kg of LEV in patients without any history of epilepsy leads to changes in rCBF in areas known to be affected in the early stages of AD. These areas may be the focus of the epileptiform activity. Larger studies are needed to confirm the current findings.